Neurocrine Advances NBI-1065890 Phase 2 TD Study
Event summary
- Neurocrine Biosciences initiated a Phase 2 clinical study for NBI-1065890, a VMAT2 inhibitor, targeting tardive dyskinesia (TD).
- The study will enroll approximately 100 adult TD patients and assess efficacy, safety, and tolerability against a placebo.
- The primary endpoint is change from baseline in the Abnormal Involuntary Movement Scale (AIMS) score at Week 8.
- Neurocrine previously received FDA approval for valbenazine (2017) and its expansion to Huntington’s chorea (2023).
The big picture
Neurocrine is attempting to extend its leadership in the TD treatment market, currently dominated by valbenazine. NBI-1065890 represents a bet on further refinement of VMAT2 inhibition, potentially addressing unmet needs for longer-acting or more effective therapies. The Phase 2 trial results will be crucial in determining whether NBI-1065890 can carve out a significant share of the estimated 800,000 TD patients in the U.S.
What we're watching
- Clinical Efficacy
- The AIMS score change at Week 8 will be a critical indicator of NBI-1065890’s potential to outperform existing treatments, including valbenazine, and will inform the likelihood of Phase 3 progression.
- Competitive Landscape
- The success of NBI-1065890 will depend on its ability to demonstrate a differentiated profile, particularly regarding duration of action, compared to valbenazine and any emerging competitors in the TD treatment space.
- Regulatory Pathway
- Given Neurocrine's established VMAT2 inhibitor expertise and existing FDA approvals, the regulatory pathway for NBI-1065890 will be closely scrutinized for any potential differences or accelerated review opportunities.
Related topics